Clinical Experience With Topotecan

摘要: Topotecan (Hycamtin, GlaxoSmithKline) is a water-soluble semisynthetic derivative of camptothecin (CPT), an alkaloid extracted from the stem wood Chinese tree Camptotheca acuminata (1). As result its anticancer activity and favorable toxicity profile, in 1996, topotecan was approved for use United States as antitumor agent treatment recurrent ovarian cancer. In 1998, it second-line patients with small-cell lung cancer (SCLC). Clinical trials have also assessed myelodysplastic syndrome, pancreatic, head neck, myeloma, prostate, renal cell, melanoma, gliomal, uterine, cervical, hepatocellular, gastric, breast cancers. Numerous ongoing are evaluating role combination chemotherapy. The current dosing regimen by Food Drug Administration (FDA) 30-minute intravenous (iv) infusion 1.5 mg/m2 daily 5 days, which repeated every 3 weeks. available parenteral preparation supplied vials containing 4 mg, reconstituted mL sterile water. resulting 1 mg/mL solution further diluted 5% dextrose or 0.9% saline before injection.